These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29263689)

  • 21. Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review.
    Tfelt-Hansen P; Diener HC; Steiner TJ
    Cephalalgia; 2020 Jan; 40(1):122-126. PubMed ID: 31547694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of erenumab in women with a history of menstrual migraine.
    Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
    J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Wright IK; Chou DE; Klatt J; Picard H; Lenz RA; Mikol DD
    Neurology; 2020 Aug; 95(5):e469-e479. PubMed ID: 32636324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials.
    Masoud AT; Hasan MT; Sayed A; Edward HN; Amer AM; Naga AE; Elfil M; Alghamdi BS; Perveen A; Ashraf GM; Bahbah EI
    J Neurol Sci; 2021 Aug; 427():117505. PubMed ID: 34082147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.
    Deng H; Li GG; Nie H; Feng YY; Guo GY; Guo WL; Tang ZP
    BMC Neurol; 2020 Feb; 20(1):57. PubMed ID: 32061264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
    Silvestro M; Tessitore A; Scotto di Clemente F; Tedeschi G; Russo A
    Headache; 2020 Jun; 60(6):1187-1195. PubMed ID: 32359106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.
    Israel H; Neeb L; Reuter U
    Curr Pain Headache Rep; 2018 Apr; 22(5):38. PubMed ID: 29623520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
    Raffaelli B; Reuter U
    Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular safety of erenumab for migraine prevention.
    Kudrow D; Pascual J; Winner PK; Dodick DW; Tepper SJ; Reuter U; Hong F; Klatt J; Zhang F; Cheng S; Picard H; Eisele O; Wang J; Latham JN; Mikol DD
    Neurology; 2020 Feb; 94(5):e497-e510. PubMed ID: 31852816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
    Front Neurol; 2021; 12():788159. PubMed ID: 35069416
    [No Abstract]   [Full Text] [Related]  

  • 33. The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review.
    Vig SJ; Garza J; Tao Y
    Headache; 2022 Nov; 62(10):1256-1263. PubMed ID: 35467013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erenumab: First Global Approval.
    Markham A
    Drugs; 2018 Jul; 78(11):1157-1161. PubMed ID: 29968151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes.
    Schoenen J; Timmermans G; Nonis R; Manise M; Fumal A; Gérard P
    Front Neurol; 2021; 12():805334. PubMed ID: 34956071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
    Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inpatient Constipation Among Migraine Patients Prescribed Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies and Standard of Care Antiepileptic Drugs: A Retrospective Cohort Study in a United States Electronic Health Record Database.
    Chomistek AK; Hoffman V; Urman R; Gill KS; Ezzy SM; Zhou L; Park AS; Loop B; Lopez-Leon S; McAllister P; Wang FT
    Pain Ther; 2022 Dec; 11(4):1415-1437. PubMed ID: 36203078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.
    de Hoon J; Van Hecken A; Vandermeulen C; Yan L; Smith B; Chen JS; Bautista E; Hamilton L; Waksman J; Vu T; Vargas G
    Clin Pharmacol Ther; 2018 May; 103(5):815-825. PubMed ID: 28736918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
    Diener HC; Ashina M; Ritter S; Paiva Da Silva Lima G; Rasmussen S; Zielman R; Tfelt-Hansen P
    Cephalalgia; 2021 Oct; 41(11-12):1262-1267. PubMed ID: 33939497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine.
    Bussiere JL; Davies R; Dean C; Xu C; Kim KH; Vargas HM; Chellman GJ; Balasubramanian G; Rubio-Beltran E; MaassenVanDenBrink A; Monticello TM
    Regul Toxicol Pharmacol; 2019 Aug; 106():224-238. PubMed ID: 31085251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.